Jeffrey Allen Bailey
Net Worth
Last updated:
What is Jeffrey Allen Bailey net worth?
The estimated net worth of Mr. Jeffrey Allen Bailey is at least $3,198,620 as of 9 Mar 2022. He owns shares worth $198,820 as insider and has received compensation worth at least $2,999,800 in BioDelivery Sciences International, Inc..
What is the salary of Jeffrey Allen Bailey?
Mr. Jeffrey Allen Bailey salary is $599,960 per year as Chief Executive Officer & Director in BioDelivery Sciences International, Inc..
How old is Jeffrey Allen Bailey?
Mr. Jeffrey Allen Bailey is 62 years old, born in 1963.
What stocks does Jeffrey Allen Bailey currently own?
As insider, Mr. Jeffrey Allen Bailey owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| BioDelivery Sciences International, Inc. (BDSI) | Chief Executive Officer & Director | 35,567 | $5.59 | $198,820 |
What does BioDelivery Sciences International, Inc. do?
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.
Jeffrey Allen Bailey insider trading
BioDelivery Sciences International, Inc.
Mr. Jeffrey Allen Bailey has made only one insider trade between 2020-2022, according to the Form 4 filled with the SEC.
As of 9 Mar 2022 he still owns at least 35,567 units of BDSI stock.
BioDelivery Sciences International key executives
BioDelivery Sciences International, Inc. executives and other stock owners filed with the SEC:
- Dr. Thomas B. Smith FAAFP, M.D. (64) Chief Medical Officer
- Mr. James Vollins J.D. (56) Gen. Counsel, Chief Compliance Officer & Corporation Sec.
- Mr. Jeffrey Allen Bailey (62) Chief Executive Officer & Director
- Mr. Scott M. Plesha (60) Pres & Chief Commercial Officer